Rathbones Group PLC Has $11.14 Million Holdings in Pfizer Inc. $PFE

Rathbones Group PLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 447,525 shares of the biopharmaceutical company’s stock after selling 27,010 shares during the period. Rathbones Group PLC’s holdings in Pfizer were worth $11,143,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PFE. Horizon Financial Services LLC grew its position in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Pfizer during the 4th quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the 3rd quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $30,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. Royal Bank Of Canada assumed coverage on shares of Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target for the company. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.19.

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.85 on Tuesday. The company has a 50 day moving average of $27.13 and a 200-day moving average of $25.87. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $28.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market cap of $158.35 billion, a PE ratio of 20.48 and a beta of 0.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.